Lipocine (LPCN) Change in Account Payables (2012 - 2025)
Lipocine's (LPCN) quarterly Change in Account Payables came in at $418458.0 in Q3 2025, up 356.01% YoY from $91764.2 in Q3 2024, and up 405.66% on a QoQ basis from $82755.0 in Q2 2025.
Lipocine (LPCN) Change in Account Payables (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Change in Account Payables data on file, last reported at $418458.0 in Q3 2025.
- Quarterly Change in Account Payables rose 356.01% year-over-year to $418458.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $576105.0 (up 170.63% YoY) and the FY2024 annual result came in at -$1.1 million, down 241.31% from the prior year.
- Change in Account Payables climbed to $418458.0 in Q3 2025, from $82755.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $583481.0 in Q3 2023 to a low of -$1.0 million in Q1 2021.
- A 5-year average of -$38724.6 and a median of -$13651.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 1080.81% — and 2024, when it sank 469.49%.
- Tracing LPCN's Change in Account Payables over 5 years: stood at $563790.0 in 2021, then plunged by 105.33% to -$30068.0 in 2022, then surged by 1080.81% to $294909.0 in 2023, then plunged by 104.63% to -$13651.0 in 2024, then surged by 3165.4% to $418458.0 in 2025.
- The last three Change in Account Payables figures came in at $418458.0 (Q3 2025), $82755.0 (Q2 2025), and $88543.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 418,458.00 |
| Sep 30, 2025 | 418,458.00 |
| Jun 30, 2025 | 82,755.00 |
| Jun 30, 2025 | 82,755.00 |
| Mar 31, 2025 | 88,543.00 |
| Mar 31, 2025 | 88,543.00 |
| Dec 31, 2024 | -13,651.00 |
| Dec 31, 2024 | -13,651.00 |
| Sep 30, 2024 | -163,451.00 |
| Sep 30, 2024 | -163,451.00 |
| Jun 30, 2024 | -222,647.00 |
| Jun 30, 2024 | -222,647.00 |
| Mar 31, 2024 | -724,532.00 |
| Mar 31, 2024 | -724,532.00 |
| Dec 31, 2023 | 294,909.00 |
| Dec 31, 2023 | 294,909.00 |
| Sep 30, 2023 | 583,481.00 |
| Sep 30, 2023 | 583,481.00 |
| Jun 30, 2023 | -278,889.00 |
| Jun 30, 2023 | -278,889.00 |